KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7330-7334

  Venstrom, Jeffrey M ^a   Zheng, Junting ^a   Noor, Nabila ^a   Danis, Karen E ^a   Yeh, Alice W ^a   Cheung, Irene Y ^a   Dupont, Bo ^a   O'Reilly, Richard J ^a   Cheung, Nai Kong V ^a   Hsu, Katharine C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HIGH RISK PATIENT; HLA GENE; HUMAN; KIR GENE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROBLASTOMA; ONCOGENE C MYB; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ALGORITHMS; CHILD, PRESCHOOL; DISEASE PROGRESSION; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; INFANT; LIGANDS; NEUROBLASTOMA; ODDS RATIO; RECEPTORS, KIR; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 73149091818     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1720     Document Type: Article

References (41)

1. Brodeur G, Maris J, editors. Neuroblastoma. 5th ed Philadelphia: Lippincott; 2006.
2. Cohn S, Pearson A, London W, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
3. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004;26:791-6.
4. Castriconi R, Dondero A, Cilli M, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007;56:1733-42.
5. Castriconi R, Dondero A, Corrias M, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004;64:9180-4.
6. Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-3 as a neuroblastoma-associated molecule that exerts a protective role fromanNK cell-mediated lysis. Proc Natl Acad Sci U S A 2004;101:12640-5.
7. Hellstrom I, Hellstrom K, Pierce G, Bill A. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A 1968;60:1231-8.
8. Fernandez N, Treiner E, Vance R, Jamieson A, Lemieux S, Raulet D. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-23.
9. Yu J, Heller G, Chewning J, Kim S, Yokoyama W, Hsu K. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007;179:5977-89.
10. Kim S, Sunwoo J, Yang L, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008;105:3053-8.
11. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331-42.
12. Ljunggren HG, Karre K. In search of the missing self: MHC molecules and NK recognition. Immunol Today 1990;11:237-44.
13. Kim S, Poursine-Laurent J, Truscott S, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-13.
14. Natarajan K, Dimasi N, Want J, Mariuzza R, Margulies D. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-85.
15. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-51.
16. 2-microglobulin-deficient mice. J Exp Med 1992;175:885-93.
17. Cooley S, Xiao F, Pitt M, et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature. Blood 2007;110:578-86.
18. Sun J, Lanier L. Cutting edge: viral infection breaks NK cell tolerance to "missing self". J Immunol 2008;181:7453-7.
19. Yu J, Venstrom J, Liu X, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneichematopoieticc ell transplantation. Blood 2009;113:3875-84.
20. Hsu K, Keever-Taylor C, Wilton A, et al. Improved outcome in allogeneic hematopoietic stem cell transplantation in acute myelogenous leukemia (AML) predicted by donor KIR genotype and recipient HLA genotype in T-cell depleted HLA-identical sibling transplants. Blood 2005;105:4878-84.
21. Hsu K, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoieticc ell transplantation for hematologicmalig nancy. Biol Blood Marrow Transplant 2006;12:828-36.
22. Miller J, Cooley S, Parham P, et al. Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneicHCT. Blood 2007;109:5058-61.
23. Clausen J, Wolf D, Petzer A, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen identical haematopoietics tem cell transplantation. Clin Exp Immunol 2007;148:520-8.
24. Kushner B, Kramer K, LaQuaglia M, Modak S, Yataghene K, Cheung N. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888-92.
25. Kushner B, Kramer K, Modak S, Cheung N. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res 2004;10:84-7.
26. Kushner B, Cheung N, Kramer K, Dunkel I, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 2001;28:551-6.
27. Matthay K, Villablanca J, Seeger R, Reynolds C, Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoicac id. N Engl J Med 1999;341:1165-73.
28. Matthay K, Perez C, Seeger R, Swift P, Stram D, Lukens J. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998;16:1256-64.
29. Kushner B, Wolden S, LaQuaglia M, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001;19:2821-8.
30. Hsu KC, Liu X, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomicdi versity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002;169:5118-29.
31. Gumperz J, Barber L, Valiante N, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol 1997;158:5237-41.
32. Khakoo S, Thio C, Martin M, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-4.
33. Foley B, Santis DD, Beelen EV, Lathbury L, Christiansen F, Witt C. The reactivity of Bw4 HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008;112:435-43.
34. Thananchai H, Gillepsie G, Martin M, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007;178:33-7.
35. Cooley S, Trachtenberg E, Bergemann T, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009;113:726-32.
36. Olsen G, Gockerman J, Bast R, Borowitz M, Peters W. Altered immunologicrec onstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 1988;46:57-60.
37. Porrata L, Inwards D, Lacy M, Markovic S. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-a in autologous stem cell transplantation. Bone Marrow Transplant 2001;28:673-80.
38. Porrata L, Ingle J, litzow M, Geyer S, Markovic S. Prolonged survival associated with early lymphocyte recovery after autologous hematopoieticstem cell transplantation for patients with metastaticbreast cancer. Bone Marrow Transplant 2001;2001:865-71.
39. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay M, Hale G. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoieticstem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007;97:539-42.
40. Stern M, Paulussen M, Rischewski J, Tichelli A, Gratwohl A. Missing ligand model in autologous stem cell transplantation. Br J Cancer 2008;98:852-3.
41. Cheung N, Sowers R, Cheung I, Kushner B, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24:2885-90.